# US 2024/0189307 A1 · Methods of stabilizing the neuronal proteome against collapse and protecting vascular cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189307 A1
- Document ID: US20240189307A1
- Status: Published application
- Kind: A1
- Application number: 18/556,140
- Filed: 2022-04-21
- Published: 2024-06-13
- Earliest claimed: 2021-04-21
- Assignees: Albert Einstein College of Medicine
- Applicants: Albert Einstein College of Medicine
- Inventors: Ana Maria CUERVO; Evripidis GAVATHIOTIS
- Web page: https://patentgrep.com/patent/US20240189307A1

## CPC

- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61K 31/538: ortho- or peri-condensed with carbocyclic ring systems
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure provides method of enhancing neuronal, vascular cell, and macrophage proteostasis, in a subject by administering a CMA activator to the subject. Enhancing proteostasis is a method of preventing or slowing advancement of an age-related neurodegenerative disease, atherosclerosis, or an inflammatory disease in a subject. The age related neurodegenerative disease can be Alzheimer A disease (AD), Lewy body dementia, Parkinson's disease (PD), Huntington's disease, Amyotrophic lateral sclerosis (ALS), Frontotemporal dementia (FTD). Spinocerebellar ataxias (SC As), or Progressive subcortical gliosis. The disclosure further provides a method of reducing the progression of beta-amyloid and/or tau pathology in the subject, and/or reduces pre-existing beta-amyloid and/or tau pathology in the subject.

## Claims

### Claim 1

A method of preventing or slowing advancement of an age-related neurodegenerative disease in a subject in need thereof, comprising
identifying an early symptom or biomarker of the neurodegenerative disease in the subject, and
administering a therapeutically effective amount of a CMA activator to the subject,
wherein the subject is asymptomatic or is in an early symptomatic stage of the age-related neurodegenerative disease,
wherein administering the CMA activator reduces the progression of beta-amyloid and/or tau pathology in the subject, and/or reduces pre-existing beta-amyloid and/or tau pathology in the subject.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1, the biomarker is beta-amyloid or tau and the method further comprises determining the progression of beta-amyloid and/or tau pathology by positron emission tomography (PET) and/or magnetic resonance (MR) imaging.

### Claim 4 (depends on 1)

The method of claim 1, wherein administering the CMA inhibitor reduces gliosis in the brain of the subject, for example as determined by positron emission tomography (PET) and/or magnetic resonance (MR) imaging.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject is suffering from mild cognitive impairment.

### Claim 6 (depends on 1)

The method of claim 1, wherein the age-related neurodegenerative disease is Alzheimer's disease (AD), Lewy body dementia, Parkinson's disease (PD), Huntington's disease, Amyotrophic lateral sclerosis (ALS), Frontotemporal dementia (FTD), Spinocerebellar ataxias (SCAs), and Progressive subcortical gliosis.

### Claim 7 (depends on 1)

The method of claim 1, wherein the neurodegenerative disease is AD, and the subject does not suffer from dementia.

### Claim 8 (depends on 1)

The method of claim 1, wherein the neurodegenerative disease is AD, and the early symptom is memory loss and/or confusion, difficulty concentrating, difficulty completing daily tasks, time and/or place confusion, difficulty with visual images and/or spatial relationships, difficulty conversing, misplacing objects, poor judgment, withdrawal from activities, olfactory dysfunction, changes in mood and personality.

### Claim 9 (depends on 1)

The method of claim 1, wherein the neurodegenerative disease is AD, and the biomarker is tau protein (total tau or phosphorylated tau) or beta-amyloid (e.g., Aβ42) in the plasma or cerebrospinal fluid (CSF) of the subject; or
the neurodegenerative disease is PD and the early symptom is slight tremors in the fingers, thumbs, hand or chin; small handwriting (also called micrographia); loss of smell; difficulty sleeping including sudden movements in sleep; difficulty moving or walking; constipation; a soft or low voice; facial masking; impaired memory; dizziness or fainting; or stooping, leaning and/or slouching while standing.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The method of claim 1, further comprising detecting an increase in neuronal glycolysis after administering the CMA activator.

### Claim 12

A method of enhancing neuronal, vascular cell, or macrophage proteostasis in a subject in need of treatment for an age-related neurodegenerative disorder, comprising
administering a CMA activator to the subject, and
detecting an increase in neuronal glycolysis after administering the CMA activator wherein administering the CMA activator enhances neuronal proteostasis in the subject and reduces the progression of beta-amyloid and/or tau pathology in the subject, and
the method optionally further comprises determining the progression of beta-amyloid and/or tau pathology by positron emission tomography (PET) and/or magnetic resonance (MR) imaging, or by tau protein (total tau or phosphorylated tau) or beta-amyloid (e.g., Aβ42) in the plasma or cerebrospinal fluid (CSF) of the subject.

### Claim at position 13

13-16. (canceled)

### Claim 17

A method of maintaining glycolytic activity in neurons of a patient. comprising
administering an amount of a Chaperone Mediated Autophagy (CMA) activator to the patient sufficient to activate CMA in the excitatory and/or inhibitory neurons of the patient; and thereby maintaining glycolytic activity in the patient's neurons.

### Claim 18

A method of reducing the level of a marker Alzheimer's Dementia (AD) pathology or slowing the increase of a marker of AD pathology in a patient diagnosed as at risk of developing AD or in a patient diagnosed as having AD, comprising
determining a first level of the marker of AD pathology in the patient
administering an amount of a Chaperone Mediated Autophagy (CMA) activator to the patient sufficient to activate CMA in the neurons of the patient daily for a period of at least 3 months, at least 6 months, or at least 12 months; and
determining a second level of the marker of AD pathology in the patient after the administration of the CMA activator;
comparing the first level and the second level of the marker AD pathology; and determining whether the level of the marker of AD pathology has decreased or slowed in the patient; wherein the marker of AD pathology is a phosphorylation of tau, oligomerization of tau, an increase in beta-amyloid, an increase insoluble tau, or an increase in α-synuclein protein.

### Claim at position 16

19-26. (canceled)

### Claim 27

A method of preventing, reducing, or slowing advancement of atherosclerotic disease in a subject, comprising
identifying an early symptom or biomarker of atherosclerotic disease in the subject, or identifying the presence of an arterial plague or arterial fatty streak in the subject, and
administering a therapeutically effective amount of a chaperone-mediated autophagy (CMA) activator to the subject,
wherein the subject is asymptomatic or is in an early symptomatic stage of the atherosclerotic disease;
wherein a sufficient amount of the CMA activator is administered to reduce the fraction cholesterol and/or triglycerides in the VLDL and LDL fractions of the subject relative to the level of cholesterol and/or triglycerides in the VLDL and LDL fractions prior to administration of the CMA activator.

### Claim 28

(canceled)

### Claim 29 (depends on 27)

The method of claim 27, wherein the biomarker is vascular smooth muscle cell (VSMC) dedifferentiation or C-reactive protein (CRP) level and the advancement of atherosclerotic disease is monitored by angiogram, chest x-ray, CT scan, echocardiogram, electrocardiogram, intravascular ultrasound, exercise stress test, positron emission tomography (PET) and/or magnetic resonance (MR) imaging.

### Claim 30 (depends on 27)

The method of claim 27, wherein administering the CMA activator reduces arterial plaque in the subject, relative to the level of arterial plague in the subject prior to administration of the CMA activator.

### Claim 31 (depends on 27)

The method of claim 27, wherein the subject has observable arterial plaques or arterial fatty streak but does not have insufficient blood flow.

### Claim at position 22

32-35. (canceled)

### Claim 36

A method of reducing a C-reactive protein level in a subject identified as at risk of developing atherosclerosis, comprising:
determining a first level C-reactive protein in the patient; and
administering an amount of a Chaperone Mediated Autophagy (CMA) activator to the patient sufficient to activate CMA in the vascular tissue of the patient; wherein the CMA activator is administered at least once daily for a period of at least 6 weeks, at least 3 months, at least 6 months, or at least 12 months;
determining a second level of the marker of C-reactive protein in the patient after the period of administration of the CMA activator; and
comparing the first level and the second level of the C-reactive protein in the subject.

### Claim 37

A method of reducing the risk of a stroke in a subject who has already experienced at least one stroke, comprising administering a therapeutically effective amount of a CMA activator to the subject.

### Claim at position 25

38-39. (canceled)